Simulations Plus, Inc. (SLP) 株式分析

企業概要

Simulations Plus, Inc. is a global enterprise dedicated to advancing drug discovery and development by providing specialized software for modeling, simulation, and the prediction of molecular properties through the application of artificial intelligence and machine learning technologies. The company operates within the Healthcare sector, specifically classified under the Health Information Services industry, which positions it as a provider of critical digital infrastructure for the pharmaceutical and biotechnology research ecosystems. According to the latest available data, the firm's market capitalization stands at $261.91M, supported by an annual revenue of $78.68M and an employee base of 212 individuals. These valuation and revenue figures indicate that the company maintains a mid-cap profile within its niche, suggesting a business model that relies on high-value specialized software rather than mass-market consumer products, thereby reflecting a position where scale is achieved through technological depth and customer concentration in the life sciences sector.

財務健全性

The company reported a trailing twelve-month revenue of $78.68M, yet this generated a net income of -$64.248M, revealing a significant divergence between top-line performance and bottom-line profitability that points to substantial non-operating expenses or one-time charges impacting the income statement. Despite the negative net income, the company maintained a positive EBITDA of $11.77M, indicating that core operational cash generation remains intact even when accounting for interest, taxes, depreciation, and amortization. Financial flexibility is further evidenced by a free cash flow of $15.19M, which demonstrates the ability to generate liquidity independent of non-cash accounting adjustments and provides a buffer for operational needs or strategic investments. The margin structure presents a mixed picture, with a gross margin of 59.6% reflecting strong pricing power or low cost of goods sold typical of software firms, contrasted against an operating margin of 3.9% and a profit margin of -81.7% that highlights significant operating leverage challenges or high SG&A expenses relative to revenue. On the balance sheet, the company holds $35.69M in cash against a minimal debt obligation of $557,000, resulting in a debt-to-equity ratio of 0.44, which characterizes the capital structure as highly conservative and low-leveraged. This liquidity position is reinforced by a current ratio of 5.62, a metric that signals robust short-term liquidity and a substantial ability to meet obligations as they come due without distress. Finally, the return metrics show a return on equity of -41.2% and a return on assets of 2.8%, suggesting that while asset utilization is positive, the negative equity return currently reflects the impact of recent earnings volatility on shareholders' book value.

バリュエーション評価

The valuation multiples present a complex picture, with a trailing P/E ratio listed as N/A due to the negative earnings, while the forward P/E stands at 12.21, implying that the market prices the stock based on anticipated future profitability rather than historical performance. The price-to-book ratio is recorded at 2.06, indicating that the market values the company at more than twice its tangible book value, which often suggests confidence in the intangible assets and future growth potential inherent in the software business model. Alternative valuation metrics such as the price-to-sales ratio of 3.33 and an EV/EBITDA of 19.27 provide context, suggesting the company is valued at a premium relative to its sales and enterprise earnings, consistent with firms in the specialized health information services sector. Regarding trading range, the 52-week high is $36.45 and the 52-week low is $11.09; however, without a specific current share price provided in the facts, the exact percentage deviation from these levels cannot be calculated, though the wide range indicates significant price volatility over the past year. The beta value is 1.19, which signifies that the stock's price volatility is approximately 19% higher than that of the broader market, reflecting the higher risk profile associated with small-cap biotech software companies.

Growth & Income

Growth dynamics show a revenue decline of -2.7% year-over-year, while earnings growth is listed at 200.0%, a metric that implies a normalization of earnings from a prior negative baseline rather than an expansion of absolute profit magnitude. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm retains all of its earnings to reinvest in research, development, and software expansion rather than distributing cash to shareholders. The disparity between the negative revenue growth and the positive earnings growth rate underscores the company's current focus on cost management and efficiency improvements to stabilize profitability despite a contraction in sales. Overall, the growth and income profile is defined by a period of earnings recovery and cash flow generation, where the absence of dividend payouts aligns with a capital allocation strategy focused on sustaining the company's technological edge in the competitive health information services landscape.